Ocular Therapeutix Inc (OCUL)
6.17
+0.30
(+5.11%)
USD |
NASDAQ |
May 03, 16:00
6.16
-0.01
(-0.16%)
After-Hours: 20:00
Ocular Therapeutix Cash from Financing (Quarterly): 108.17M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 108.17M |
| September 30, 2023 | 51.94M |
| June 30, 2023 | 9.645M |
| March 31, 2023 | 0.078M |
| December 31, 2022 | 0.458M |
| September 30, 2022 | 0.374M |
| June 30, 2022 | 0.493M |
| March 31, 2022 | 0.129M |
| December 31, 2021 | 0.667M |
| September 30, 2021 | 0.679M |
| June 30, 2021 | 2.667M |
| March 31, 2021 | -1.162M |
| December 31, 2020 | 163.91M |
| September 30, 2020 | 0.22M |
| June 30, 2020 | 51.06M |
| March 31, 2020 | 12.82M |
| December 31, 2019 | 9.091M |
| September 30, 2019 | 18.61M |
| June 30, 2019 | 5.338M |
| March 31, 2019 | 42.30M |
| December 31, 2018 | 16.33M |
| September 30, 2018 | 11.37M |
| Date | Value |
|---|---|
| June 30, 2018 | 6.712M |
| March 31, 2018 | 34.23M |
| December 31, 2017 | 1.206M |
| September 30, 2017 | 1.529M |
| June 30, 2017 | 0.796M |
| March 31, 2017 | 28.48M |
| December 31, 2016 | 0.693M |
| September 30, 2016 | 0.078M |
| June 30, 2016 | 0.003M |
| March 31, 2016 | -0.189M |
| December 31, 2015 | 0.308M |
| September 30, 2015 | -0.201M |
| June 30, 2015 | 65.73M |
| March 31, 2015 | -0.137M |
| December 31, 2014 | -0.106M |
| September 30, 2014 | 67.56M |
| June 30, 2014 | 11.95M |
| March 31, 2014 | -0.433M |
| December 31, 2013 | -0.449M |
| September 30, 2013 | -0.454M |
| June 30, 2013 | 8.041M |
| March 31, 2013 | -0.455M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.162M
Minimum
Mar 2021
163.91M
Maximum
Dec 2020
22.90M
Average
2.667M
Median
Jun 2021
Cash from Financing (Quarterly) Benchmarks
| Amgen Inc | -1.708B |
| Assertio Holdings Inc | -8.915M |
| CytomX Therapeutics Inc | 0.244M |
| EyePoint Pharmaceuticals Inc | 218.48M |
| Regeneron Pharmaceuticals Inc | 47.10M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -22.45M |
| Cash from Investing (Quarterly) | -0.459M |
| Free Cash Flow | -76.32M |
| Free Cash Flow Per Share (Quarterly) | -0.2539 |
| Free Cash Flow to Equity (Quarterly) | -23.95M |
| Free Cash Flow Yield | -14.96% |